Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Pavan Reddy (NPI 1932161155)

Field	Value
Entity Type	Individual
Organization	Pavan Reddy
Address	818 N Emporia St Ste 403
City	Wichita
State	KS
ZIP	67214
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 4, 2006

Payer Source	Total Paid
Medicare	$6.7M
Medicaid	$0

Key Findings

The provider’s code mix is consistent with an infusion-oriented hematology & oncology practice that administers high-cost immunotherapies and monoclonal antibodies in-office. Top injectable oncology agents in the portfolio include pembrolizumab (J9271), nivolumab (J9299), and daratumumab (J9145), and the presence of high-volume chemotherapy administration codes (96413) and multiple supportive-care injectables indicates a clinically integrated infusion service line rather than a primarily consultative or referral-only model.

Revenue is highly concentrated in a small set of products: the top 3 Medicare codes by revenue account for 49.7% of this provider’s total Medicare revenue. Those top-three contributors are J9271 ($1.5M, 24.3% of Medicare revenue), J9299 ($934.1K, 14.9%), and J9145 ($658.1K, 10.5%), together forming the largest single block of billed Medicare dollars for this provider.

This provider is effectively single-payer in scope: total Medicare revenue is $6.7M while there is no Medicaid billing on file. The absence of Medicaid activity means payer strategy, capacity, and financial exposure will be dominated by Medicare reimbursement dynamics and inpatient/outpatient Medicare policy changes.

For several high-value oncology drugs this provider reports national-level volumes well above peers: J9271 ranks #58 of 1841 providers nationally (97th percentile) and is described as notably above typical national volume, while J9299 ranks #34 of 505 (93rd percentile) and is also notably above typical national volume. In contrast, J9145 sits at a more typical level for its market (rank #5 of 14, 69th percentile), indicating that the provider’s outsized footprint is concentrated in specific immuno-oncology agents rather than uniformly across all monoclonals.

Advanced imaging is a material revenue stream: PET/CT 78815 generated $423.7K (6.8% of Medicare revenue) and ranks #356 of 6566 providers nationally (95th percentile), reported as notably above typical national volume. High utilization of fused PET/CT suggests frequent use of staging and response-evaluation imaging in conjunction with the provider’s infusion treatments, reinforcing the integrated diagnostic-treatment workflow.

Operational volume metrics show several statistical outliers on common outpatient visit and chemotherapy administration codes: 99213 produced $117.5K (1.9% of Medicare revenue) and ranks #967 of 457151 providers nationally (100th percentile; labeled an extreme outlier), and 96413 produced $108K (1.7%) and ranks #38 of 7514 providers nationally (100th percentile; extreme outlier). These extreme outlier rankings indicate unusually high visit and administration throughput relative to national peers, consistent with a high-volume infusion practice.

Supportive-care and ancillary therapy patterns are notable: denosumab (J0897) appears at $371.6K (5.9% of Medicare revenue) with a rank of #303 of 10057 (97th percentile; notably above typical national volume), and granisetron extended-release (J1627) ranks #8 of 119 providers nationally (94th percentile). The provider also uses biosimilars (Q5115, Q5107) at modest-to-typical levels, indicating adoption of biosimilar alternatives alongside originator biologics rather than exclusive reliance on one product class.

The NPI was enumerated on 2006-04-04 (~20 years ago), indicating long tenure in the market. Coupled with high national-percentile ranks on multiple drug-administration and visit codes, this tenure is consistent with an established, practice-based oncology operation that has built sustained infusion capacity over time.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

117 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	35,400	$40	$1.5M
J9299	Injection, nivolumab, 1 mg	38,920	$20	$934.1K
J9145	Injection, daratumumab, 10 mg	15,670	$40	$658.1K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	400	$1,070	$423.7K
J1930	Injection, lanreotide, 1 mg	9,120	$40	$383K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	9,540	$40	$372.1K
J0897	Injection, denosumab, 1 mg	19,560	$20	$371.6K
J9022	Injection, atezolizumab, 10 mg	3,240	$60	$207.4K
J9173	Injection, durvalumab, 10 mg	3,110	$60	$192.7K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,930	$30	$133.6K

Showing 1–10 of 117

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 117 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Pavan Reddy — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

117 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	4	20	28,900	$40	$1.1M
J9299	3	10	24,550	$20	$637.2K
J1930	4	10	9,180	$40	$402.7K
J9145	1	10	6,660	$50	$394.7K
J9022	4	10	3,910	$60	$301.1K
J9144	2	10	6,300	$40	$257.2K
J9173	5	10	3,480	$60	$230.3K
J9312	8	10	2,500	$60	$194.7K
J1568	5	10	3,690	$30	$129K
Q5107	7	10	4,440	$20	$106.5K

Showing 1–10 of 117

Related Providers

Other providers that share a Tax Identification Number (TIN) with Pavan Reddy, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ascension Via Christi Hospitals Wichita Inc.	KS	General Acute Care Hospital	$0	$8.9M
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Dennis Moore	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Pavan Reddy, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Craig Resources LLC	KS	Home Health Agency	$0	$97.3M
Paradigm Services Inc	KS	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$42.4M
Wesley Medical Center LLC	KS	General Acute Care Hospital	$0	$30.2M
Gracemed Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$18.3M
Healthcore Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$15.3M
Diversified Family Services LLC	KS	Home Health Agency	$0	$13.9M
Alpha Service	KS	Developmentally Disabled Services Day Training Agency	$0	$12.1M
Carepoint Emergency Medicine Kansas LLC	KS	Emergency Medicine Physician	$0	$11.8M
Hunter Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$10.4M
Infusion LLC	KS	Home Infusion Therapy Pharmacy	$0	$6.5M

Pavan Reddy — Billing Profile & Reimbursement Data

Sign up for Pavan Reddy — Billing Profile & Reimbursement Data policy alerts

Pavan Reddy — Billing Profile & Reimbursement Data

Sign up for Pavan Reddy — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References